Dahan Michel

Avg. Two Year Performance

No purchase track record

44% Avg. Sale Return

20% Compound

	1 Mo	3 Mo	6 Mo	1 Yr	2 Yr
Average Purchase Return	--	--	--	--	--
Purchase Success Rate	--	--	--	--	--
Average Sale Return	2%	(2%)	8%	21%	44%
Sale Success Rate	6 of 11	3 of 11	4 of 11	4 of 11	7 of 11

Akebia Therapeutics, Inc.

Drugs » Biotechnology

SVP, Chief Operating Officer:

Holdings: 672.09K shares

Sentiment

Avg. Two Year Performance

No purchase track record

No sale track record

Last Three Months:

0 Net Amount

Buy:	0	--
Sell:	0	--